Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2)
Article, 2010
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 20100120, 509
2010